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Objetive. Preliminary toxicity analysis of chemotherapy FLOX schedule as adjuvant treatment in stage III of rectal cancer.
Methods. From August/06 to May/12, 13 consecutive patients (p) with pathological stage III rectal cancer were treated with FLOX
as adjuvant chemotherapy after pre-operative chemo-radiotherapy (5-Fluorouracil 2 cycles with pelvic radiotherapy 50.4Gy) and
radical surgery. FLOX schedule included: 5-ﬂuorouracil bolus 500mg/m2 with leucovorin 500mg/m2 days 1, 8, 15, 21, 29 and 36
and oxaliplatin 85 mg/m2 days 1, 15 and 29, every 8 weeks for a total 2 cycles. Haematological and clinical toxicity evaluation
every week was performed.
Results. Median age: 60 years (range 46–68). Male/female: 7/6. Histological Grades G1/G2/G3: 1/10/2. Pathological stage IIIA/IIIB/IIIC:
3/9/1. A total of 23 cycles were delivered over 26 planned. Main CTC toxicity for p was: Anaemia G 1+2 in 9, Neutropenia G 1+2
in 6 and G 3 in 5, Plaquetopenia G 1+2 in 5, Nausea and emesis G 1+2 in 4, Diarrhea G 1+2 in 3 and G 3+4 in 5, and Neurotoxicity
G1+2 in 7 p. No toxic deaths were observed. In relation to Neutropenia G 3 and Diarrhea G 3–4 two p were hospitalised. Only 3
p (23%) completed full treatment plan, 6 p (41%) required 80% dose reduction and/or a median of 2 week doses were cancelled,
3 p (23%) did not received the second cycle for toxicity in the ﬁrst and underwent Mayo clinic schedule, and 1 p progressed with
lung metastases during the second cycle.
Conclusions. Preliminary results suggest that FLOX chemotherapy schedule after chemo-radiotherapy and surgery in rectal
cancer have a moderate-severe toxicity proﬁle with 23% treatment interruption, 41% dose reduction and 15% hospitalization
for G 3–4 toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.200
Hemostatic radiotherapy for bleeding from an advanced gastric cancer
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Introduction. Gastric bleeding from the primary tumor frequently occurs in patients with unresectable gastric cancer, requiring
palliative treatment, including hemostatic radiotherapy (RT).
Objetive. To evaluate the effectiveness of RT with 30Gy in 10 fractions to control the bleeding from an advanced gastric cancer.
Methods. We reviewed the data from all gastric cancer patients who required blood transfusions due to gastric bleeding and were
treated with RT with hemostatic intention at Vall d’Hebron Hospital between April 2009 and October 2012. Overall 15 patients
were analyzed, with a median age of 74 years (58–85). All patients required blood transfusions previous to RT, with a median of
hemoglobin (Hb) preRT of 6.7 g/dL. Patients were treated in a lineal accelerator with a total dose of 30Gy in 10 fractions. Due to
rapid medical decline, 2 patients stopped treatment at 21 and 18Gy.
Results. The palliative effect of hemostatic RT was evaluated both in subjective and objective manner. Subjective symptomatic
relief (cessation of hematemesis and manes) was conﬁrmed through patient observation and objective response was determined
by the requirement of blood transfusions after RT, and also comparing hemoglobin levels both before and after RT. Twelve out of
15 patients (80%) responded subjectively to RT. In the ﬁrst 3 months after RT, 4 patients required blood transfusion, in 3 of those
cases these was due to hematological toxicity secondary to chemotherapy. The median of Hb before, 1 month after RT and 3
months after RT were: 6.7 g/dL (5.6–8.1), 9.7 g/dL (8.8–11.4) and 9.7 (7.6–11.4), respectively. Two patients presented bleeding again,
one case 1 month and the other one 14 months after RT.
Conclusions. Hemostatic RT is an adequate treatment of bleeding fromanadvanced gastric cancer, andRTwith 30Gy in 10 fractions
seems to be an effective schema, especially in patients with a poor prognosis.
http://dx.doi.org/10.1016/j.rpor.2013.03.201
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Introduction. Hypofractionated radiotherapy has been shown to be effective in tumor control. Short course irradiation may be a
valuable treatment option for patient convenience, cost reduction and in patients with a short life expectancy because of age or
comorbidities or patients who are unable to participate in a more prolonged course because of different problems.
Materials and method. Twenty-ﬁve patients diagnosed of rectal adenocarcinoma were treated at the Hospital de l’Esperanc¸a in
Barcelona. There were 14 patients with severe comorbidities who were unable to receive chemotherapy, 6 patients too old, who
were unable to come to our hospital 25 days because they live far from our hospital and 5 patients with a rectal tumour and
resectable liver metastases. All patients were treated with a 18 MV linear accelerator and the total dose administered was 25 Gy
in 5 fractions. Surgery was performed after 7–10 days after radiotherapy; only 5/25 patients received postoperative chemotherapy
before hepatic surgery.
